New York, June 01, 2016 -- Moody's Investors Service (Moody's) placed the ratings of PCI Pharma Midco UK Limited (PCI) under review for downgrade, including the company's B2 Corporate Family Rating and B2-PD Probability of Default Rating. The B1 rating on PCI's first lien senior secured credit facility and the Caa1 rating on the second lien senior secured term loan were also placed under review. The review was initiated by the announcement on June 1, 2016 that Partners Group has agreed to acquire PCI from Frazier Healthcare Partners (Frazier). Frazier will maintain a minority interest in PCI following the close of the transaction, which is expected in mid-July.

Vollständigen Artikel bei Moodys lesen